Idorsia (IDRSF) News Today $0.81 0.00 (0.00%) (As of 11/22/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Idorsia's once-daily TRYVIO™ (aprocitentan) is now available in the U.S., advancing treatment options for millions of patients with difficult-to-control hypertensionNovember 15, 2024 | prnewswire.comIdorsia is advancing the treatment of hypertension with new data at the 2024 American Heart Association (AHA) Scientific SessionsNovember 11, 2024 | globenewswire.comOne Idorsia Ltd (VTX:IDIA) Analyst Just Slashed Their Estimates By A Considerable 33%November 6, 2024 | finance.yahoo.comIdorsia upgraded to Hold from Sell at Deutsche BankNovember 5, 2024 | markets.businessinsider.comIdorsia rating suspended at Goldman SachsOctober 30, 2024 | markets.businessinsider.comIdorsia price target lowered to CHF 1.20 from CHF 2 at JPMorganOctober 22, 2024 | markets.businessinsider.comSome Analysts Just Cut Their Idorsia Ltd (VTX:IDIA) EstimatesOctober 20, 2024 | finance.yahoo.comIdorsia continues to further the science of sleep and insomnia with new daridorexant data and analyses published at Sleep Europe 2024September 17, 2024 | globenewswire.comAmended terms of Idorsia’s 2024 convertible bonds become effectiveSeptember 2, 2024 | uk.finance.yahoo.comIdorsia Pharmaceuticals Ltd: Amended terms of Idorsia's 2024 convertible bonds become effectiveSeptember 2, 2024 | finanznachrichten.deAmended terms of Idorsia's 2024 convertible bonds become effectiveSeptember 2, 2024 | globenewswire.comMaintaining Hold on Idorsia: Awaiting Clarity on Tryvio Partnerships and Commercialization StrategyJuly 30, 2024 | markets.businessinsider.comIdorsia Ltd (IDRSF) Q2 2024 Earnings Call TranscriptJuly 27, 2024 | seekingalpha.comIdorsia Pharmaceuticals Ltd: Idorsia announces financial results for the first half 2024July 25, 2024 | finanznachrichten.deIdorsia Ltd (VTX:IDIA) most popular amongst individual investors who own 38%, insiders hold 32%July 25, 2024 | finance.yahoo.comIdorsia Pharmaceuticals Ltd: Invitation to Idorsia's Half Year 2024 Financial Reporting webcast and conference callJuly 20, 2024 | finanznachrichten.deInvitation to Idorsia's Half Year 2024 Financial Reporting webcast and conference callJuly 18, 2024 | globenewswire.comIdorsia's JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertensionJuly 1, 2024 | globenewswire.comIdorsia's novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality' categoryJune 21, 2024 | globenewswire.comIdorsia holds its Annual General Meeting of ShareholdersJune 13, 2024 | globenewswire.comIdorsia Ltd (IDRSF)May 24, 2024 | finance.yahoo.comIdorsia issues invitation to the 2024 Annual General Meeting of ShareholdersMay 23, 2024 | globenewswire.comIdorsia announces changes to Idorsia Executive Committee and Board of DirectorsMay 21, 2024 | globenewswire.comIdorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable valueMay 21, 2024 | globenewswire.comInvitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference callMay 14, 2024 | globenewswire.comIdorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bondMay 1, 2024 | globenewswire.comIdorsia Ltd (VTX:IDIA) Analysts Just Cut Their EPS Forecasts SubstantiallyApril 27, 2024 | finance.yahoo.comJERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertensionApril 26, 2024 | finance.yahoo.comIdorsia publishes an invitation to a bondholder meetingApril 23, 2024 | globenewswire.comIdorsia publishes a Financial Status required for an upcoming bondholder meetingApril 17, 2024 | finance.yahoo.comIdorsia takes steps to address short-term liquidity needsApril 11, 2024 | globenewswire.comIdorsia gets FDA approval for high blood pressure drug TryvioMarch 22, 2024 | bizjournals.comIdorsia: Aprocitentan Approval Is A Vital NewsMarch 22, 2024 | seekingalpha.comIdorsia thanks Guy Braunstein for his years of service as he retiresMarch 22, 2024 | globenewswire.comFDA approves Idorsia’s once-daily antihypertensive TryvioMarch 20, 2024 | msn.comIdorsia gets FDA approval for hypertension drug TryvioMarch 20, 2024 | msn.comIdorsia Ltd (IDRSF) Stock Historical Prices & Data - Yahoo FinanceMarch 20, 2024 | finance.yahoo.comUS FDA approves Idorsia's once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensivesMarch 20, 2024 | globenewswire.comWhat Does The Future Hold For Idorsia Ltd (VTX:IDIA)? These Analysts Have Been Cutting Their EstimatesMarch 8, 2024 | finance.yahoo.comKepler Cheuvreux gets more bullish on Idorsia, upgrades sharesMarch 7, 2024 | realmoney.thestreet.comViatris, Idorsia Announce Global Research And Development CollaborationFebruary 28, 2024 | markets.businessinsider.comHere's what to expect from Idorsia's earningsFebruary 6, 2024 | markets.businessinsider.comIdorsia presents at the J.P. Morgan Healthcare Conference – Adapting Idorsia for sustainable value creationJanuary 10, 2024 | finance.yahoo.comIdorsia Ltd (VTX:IDIA) surges 19%; individual investors who own 41% shares profited along with insidersDecember 6, 2023 | finance.yahoo.comIdorsia Q3 Review: Not The Quarter We ExpectedOctober 25, 2023 | msn.comIdorsia GAAP EPS of CHF0.96, revenue of CHF80MOctober 24, 2023 | msn.comIdorsia announces financial results for the first nine months of 2023 – adapting the company to create sustainable valueOctober 24, 2023 | finance.yahoo.comIdorsia Shares Fall on Funding NeedsOctober 24, 2023 | marketwatch.comIdorsia is committed to further the science of sleep with a symposium and poster presentations at World Sleep 2023October 23, 2023 | finance.yahoo.comNICE recommends Idorsia’s chronic insomnia treatment for UK patientsSeptember 15, 2023 | msn.com Get Idorsia News Delivered to You Automatically Sign up to receive the latest news and ratings for IDRSF and its competitors with MarketBeat's FREE daily newsletter. Email Address Let’s be blunt (Ad)Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now IDRSF Media Mentions By Week IDRSF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IDRSF News Sentiment▼0.000.50▲Average Medical News Sentiment IDRSF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IDRSF Articles This Week▼00▲IDRSF Articles Average Week Get Idorsia News Delivered to You Automatically Sign up to receive the latest news and ratings for IDRSF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AGNPF News Today AKBLF News Today DRTSW News Today ARNI News Today ASPHF News Today ASCLF News Today AVCTF News Today AWKNF News Today AXIM News Today BRRGF News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:IDRSF) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Idorsia Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Idorsia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
